Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

Daxor Corporation Announces Share Buyback Program

Posted on: 01 Nov 17

New York, NY, Nov. 01, 2017 (GLOBE NEWSWIRE) -- Daxor Corporation, (NYSE MKT: DXR) an investment company with medical instrumentation and biotechnology operations, announced today that an updated buyback program has been unanimously approved by Daxor’s Board of Directors. 

The Board of Directors of Daxor has voted to re-authorize the company’s share buyback for an amount of up to 300,000 shares for the next 12 months.  The Company formerly had in place a program that authorized up to 250,000 to be repurchased annually.  Stated CEO, Michael Feldschuh, “In light of the value that the shares represent at current market prices and management’s philosophy of increasing shareholder value, I welcome this policy by the Board of Directors of the Corporation.”

Daxor Corporation manufactures and markets the BVA-100 Blood Volume Analyzer, which is used in conjunction with Volumex, Daxor’s single-use diagnostic kit.  For more information regarding BVA and the Daxor BVA-100, visit Daxor’s website at

CONTACT: Daxor contact information: Diane Meegan Corporate Secretary 212-330-8512

Last updated on: 01/11/2017

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.